null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Avizakimab Biosimilar (Anti-IL21) Antibody (HDBS0094)

SKU HDBS0094
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein IL-21
Reactivity Human
Host Species Humanized
Isotype IgG1
€431
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Avizakimab (Anti-IL21) Biosimilar Antibody (HDBS0094)

The Avizakimab Biosimilar Anti-IL21 Antibody (AB10010) is a cutting-edge biologic designed for research involving the interleukin-21 (IL-21) pathway, a key player in immune function and autoimmune diseases. This antibody, developed as a biosimilar to the well-known Avizakimab, is highly specific and reacts with human IL-21 with high affinity, making it a valuable tool for studying the IL-21 signaling pathway.Raised in a state-of-the-art production facility, the Avizakimab Biosimilar Anti-IL21 Antibody has been rigorously validated for use in various immunoassays, including ELISA and flow cytometry.

Its ability to target and block IL-21 activity makes it an essential tool for researchers investigating the role of IL-21 in autoimmune disorders, inflammation, and cancer.By understanding the mechanisms of IL-21 and its impact on immune regulation, researchers can uncover new therapeutic targets and develop innovative treatments for a range of diseases. The Avizakimab Biosimilar Anti-IL21 Antibody opens up exciting possibilities for exploring the complex interplay between the immune system and disease pathogenesis, paving the way for novel therapeutic interventions.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose